MOTS-c
MOTS-c is a mitochondrial-derived peptide studied in cellular metabolism, insulin sensitivity, and exercise-physiology research.
How it is thought to work
Mitochondrial and metabolic signaling.
MOTS-c is a tiny peptide your mitochondria naturally produce that acts like an energy switch, telling cells to take in more glucose, burn more fat, and build more mitochondria, effects studied mainly in animals so far.
Reported side effects
The most commonly reported side effects are injection site redness or swelling, and occasional flushing, headache, or mild fatigue; more serious events like heart palpitations, insomnia, and fever have been reported by USADA and warrant stopping use and seeking medical input.
Who should avoid it
People with active cancer, those who are pregnant or breastfeeding, anyone on AMPK-activating drugs like metformin without a prescriber's input, competitive athletes subject to WADA testing, and anyone without access to a clinician if something goes wrong should all avoid MOTS-c.
What gets monitored
Waist circumference, bodyweight trend, fasting glucose if available at weeks 4-6; subjective energy notes and sleep timing at weeks 1-2; workout logs and recovery feel at weeks 3-4. [Source: Peptide Dosing Protocols]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for MOTS-c or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 5-10 mg SC 2-3 times weekly | 2-3 times weekly4 weeks · 4-week cycles | subcutaneous | Commonly published practitioner dosing range - provider confirmation required. |
| 5-10 mg per injection | 2-3 times per week or every 5 days | subcutaneous | Peptide Protocol WikiWhat it saysHide(secondary reference; provider confirmation required). |
| Standard: 5 mg · Low: 5 mg · High: 10 mg | 2 to 3 times per week4 to 8 weeks · 4-6 weeks | Subcutaneous injection | Peptide Dosing ProtocolsWhat it saysHide(secondary reference; provider confirmation required). The standard dosing is 5 mg subcutaneously, 3 times per week for 4-6 weeks. |
| Referenced at 10 mg weekly in divided doses within longevity stacking. Morning administration cited for circadian and mitochondrial alignment. | Weekly total (10 mg), divided doses · MorningCycle every few months in longevity contexts | subcutaneous | Peptide Therapy Reference Text, internal KB v4What it saysHide(Aug 2026), secondary reference; provider confirmation required. |
- 2-3 times weekly4 weeks · 4-week cycles
- subcutaneous
- Commonly published practitioner dosing range - provider confirmation required.
- 2-3 times per week or every 5 days
- subcutaneous
- Peptide Protocol Wiki
What it saysHide
(secondary reference; provider confirmation required).
- 2 to 3 times per week4 to 8 weeks · 4-6 weeks
- Subcutaneous injection
- Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). The standard dosing is 5 mg subcutaneously, 3 times per week for 4-6 weeks.
- Weekly total (10 mg), divided doses · MorningCycle every few months in longevity contexts
- subcutaneous
- Peptide Therapy Reference Text, internal KB v4
What it saysHide
(Aug 2026), secondary reference; provider confirmation required.
- Commonly 10 mg vials · Reconstitute with bacteriostatic water
- Bacteriostatic water
- Reconstitute a 10 mg vial with 1.0 mL bacteriostatic water
Common questions
What is MOTS-c?
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that activates AMPK, an enzyme that controls how cells use energy.
What is MOTS-c commonly researched for?
MOTS-c is studied in metabolic health, exercise capacity, body composition, aging, bone metabolism, and inflammation.
How is MOTS-c commonly dosed in research planning?
Common research-planning anchor is 5 mg subcutaneous, 2 to 3 times per week, in 4 to 8 week cycles.
What is the standard MOTS-c dosage chart?
Three tiers are commonly cited: a starting tier of 5 mg twice weekly for 4 weeks, a standard tier of 5 mg three times weekly for 4-6 weeks, and a higher tier of 10 mg two to three times weekly for 6-8 weeks.
How is MOTS-c reconstituted?
A 10 mg vial reconstituted with 1.0 mL of bacteriostatic water gives a 10 mg/mL concentration.
Check 10 mg in 1 mL in the calculator →How long is a typical MOTS-c cycle?
Cycles described in research planning are 4 to 8 weeks on, with an off period of similar length.
What are the main side effects of MOTS-c?
Reported side effects include injection-site redness or swelling, flushing, mild fatigue, and headache.
Why does MOTS-c sometimes cause flushing?
MOTS-c can trigger mast cell activation, which releases histamine and causes warmth, redness, or itching.
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for MOTS-c as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Glutathione is a tripeptide antioxidant central to cellular redox biology research.
Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) studied in growth-hormone axis research.
Blend of Tesamorelin (GHRH analog) and Ipamorelin (GHRP), studied for GH-axis support, visceral fat, and recovery.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.